

BIODIEM LTD ABN 20 096 845 993 Level 4, 100 Albert Rd, South Melbourne, Victoria, 3205

Phone: +613 9692 7240 Web: www.biodiem.com

Australia

Announcement

BioDiem CEO appointed Chairman of AusBiotech

Melbourne, 5 December 2014:

BioDiem's CEO, Julie Phillips has been appointed Chairman of AusBiotech, the peak biotechnology industry association in Australia. Julie's appointment was announced at the AusBiotech National Conference at the Gold Coast in October 2014.

Julie is a passionate and vocal advocate for the biotechnology sector and for the opportunity it poses for Australia. She has been a director of AusBiotech since October 2013, and is currently an industry representative on the Federal Government's Clinical Trials Advisory Committee.

Julie said: "I am very pleased to have been appointed as the Chairman of the AusBiotech Board and look forward to continuing to work on behalf of the industry in the new role to ensure that the Australian biotech industry is duly recognised and supported for its valuable contribution to our economy and our lives."

ENDS

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. BioDiem's business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. For additional information, please visit www.biodiem.com

Further information

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240 Email jphillips@biodiem.com

Twitter @biodiem